Obtacles and opportunities in the clinical development of targeted therapeutics
- 31 December 2004
- book chapter
- Published by Springer Nature
- Vol. 63, 19-41
- https://doi.org/10.1007/3-7643-7414-4_2
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Nuclear factor-κBCancer Cell, 2004
- Cancer genes and the pathways they controlNature Medicine, 2004
- Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesisOncogene, 2004
- Dynamics of cancer progressionNature Reviews Cancer, 2004
- Lateral signaling enhances TGF-β response complexityTrends in Cell Biology, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodiesThe Hematology Journal, 2001